Engineered immune cells tested in battle against blood cancer
NCT ID NCT03070327
Summary
This early-stage trial is testing the safety of a new treatment called CAR T-cell therapy for people with advanced multiple myeloma, a type of blood cancer. The treatment involves collecting a patient's own immune cells, modifying them in a lab to better target cancer cells, and then infusing them back. The study will also test if adding a drug called lenalidomide improves the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.